Back to top
more

Avid Bioservices (CDMO)

(Delayed Data from NSDQ)

$10.58 USD

10.58
445,610

-0.07 (-0.66%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $10.57 -0.01 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CDMO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Avid Bioservices, Inc falls in the month of April.

All items in Millions except Per Share data.

4/30/2024 4/30/2023 4/30/2022 4/30/2021 4/30/2020
Assets          
Cash & Equivalents 38 39 126 170 36
Receivables 17 18 21 19 9
Notes Receivable NA 0 0 0 0
Inventories 30 44 26 12 11
Other Current Assets 19 12 7 7 4
Total Current Assets 104 112 180 208 60
Net Property & Equipment 187 177 93 37 27
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 114 115 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets 5 5 5 2 1
Total Assets 337 451 430 266 108
Liabilities & Shareholders Equity 4/30/2024 4/30/2023 4/30/2022 4/30/2021 4/30/2020
Notes Payable NA 0 0 0 4
Accounts Payable 21 25 10 9 6
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses 5 9 8 9 3
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities 43 39 55 52 30
Total Current Liabilities 71 74 76 71 44
Mortgages NA 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 154 141 140 97 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases 7 2 2 0 0
Other Non-Current Liabilities NA 0 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities 276 262 255 188 66
Shareholders Equity 4/30/2024 4/30/2023 4/30/2022 4/30/2021 4/30/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 633 620 606 638 613
Retained Earnings -572 -431 -431 -560 -571
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity 61 189 175 78 42
Total Liabilities & Shareholder's Equity 337 451 430 266 108
Total Common Equity 100,060 189 175 78 42
Shares Outstanding 63.40 62.50 61.70 60.80 56.40
Book Value Per Share 1,578.23 3.03 2.83 1.28 0.74

Fiscal Year End for Avid Bioservices, Inc falls in the month of April.

All items in Millions except Per Share data.

7/31/2024 4/30/2024 1/31/2024 10/31/2023 7/31/2023
Assets          
Cash & Equivalents -99,999 -99,961 31 31 25
Receivables NA 17 19 13 16
Notes Receivable NA NA 0 0 0
Inventories NA 30 35 39 41
Other Current Assets NA 19 20 21 16
Total Current Assets NA 104 104 104 98
Net Property & Equipment NA 187 188 187 182
Investments & Advances NA NA 0 0 0
Other Non-Current Assets NA NA 0 0 0
Deferred Charges NA NA 118 117 114
Intangibles NA NA 0 0 0
Deposits & Other Assets NA 5 5 5 5
Total Assets NA 337 455 455 442
Liabilities & Shareholders Equity 7/31/2024 4/30/2024 1/31/2024 10/31/2023 7/31/2023
Notes Payable NA NA 141 0 0
Accounts Payable NA 21 20 23 23
Current Portion Long-Term Debt NA NA 0 0 0
Current Portion Capital Leases NA NA 0 0 0
Accrued Expenses NA 5 4 4 5
Income Taxes Payable NA NA 0 0 0
Other Current Liabilities NA 43 57 49 35
Total Current Liabilities NA 71 223 77 64
Mortgages NA NA 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 154 0 141 141
Long-Term Debt NA NA 0 0 0
Non-Current Capital Leases NA 7 7 8 1
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA NA 0 0 0
Total Liabilities NA 276 275 271 252
Shareholders Equity 7/31/2024 4/30/2024 1/31/2024 10/31/2023 7/31/2023
Preferred Stock NA NA 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 633 629 626 623
Retained Earnings NA -572 -449 -442 -433
Other Equity NA NA 0 0 0
Treasury Stock NA NA 0 0 0
Total Shareholder's Equity NA 61 180 184 191
Total Liabilities & Shareholder's Equity NA 337 455 455 442
Total Common Equity 0 100,060 180 184 191
Shares Outstanding 63.50 63.40 63.20 63.20 63.10
Book Value Per Share 0.00 1,578.23 2.85 2.91 3.02